Eleven years after approval, Entyvio remains the only IBD drug that acts only in the gut — and two large pharma programs have failed trying to replicate it.
Tysabri (natalizumab) blocks α4 integrin broadly — and 541 patients developed fatal brain infections. Entyvio (vedolizumab) blocks only α4β7, which binds MAdCAM-1 on gut endothelium. One Greek letter difference. Over a million patient-years, no REMS, no MRI surveillance. Takeda's $6 billion franchise is built on that subtraction — and on a head-to-head trial where vedolizumab beat Humira directly in ulcerative colitis.
One arm grabs the cancer cell. The other grabs a T-cell. The bispecific forces them together.
CAR-T cell therapy works but takes weeks to manufacture and costs $400K+ per patient. T-cell engager bispecific antibodies do the same job as an injectable drug - no cell extraction, no manufacturing delay. Ten are now FDA-approved across myeloma, lymphoma, leukemia, and solid tumors, competing directly with CAR-T in the same diseases.
Pfizer, Amgen, Lilly, Merck, and Astellas all failed at IGF-1R in cancer. Then a shelved Roche antibody became the only effective treatment for thyroid eye disease. Same receptor, completely different biology.
Five major pharmas spent two decades chasing IGF-1R as a cancer target. Every Phase 3 trial failed. The only IGF-1R drug ever approved is for thyroid eye disease — Tepezza, which generated $1.9 billion in 2024 and 8x exceeded its acquirer's peak forecast. Eleven more IGF-1R-for-TED programs are now in clinical trials, including the literal cancer-graveyard compound being resurrected by Sling Therapeutics. Targets don't travel. Disease context decides.
Nobody knew why it caused birth defects for 50 years. The answer launched a new era of drug design.
The worst drug disaster in pharmaceutical history accidentally revealed how to hijack the cell's protein disposal system. Celgene turned thalidomide derivatives into a $12.8B franchise without knowing the mechanism. When scientists finally identified the target in 2010, it launched targeted protein degradation - now one of the most promising modalities in drug development, with its first FDA-approved drug.
Two drugs finally broke through. They work only before most patients are ever diagnosed.
Alzheimer's drug development has a 99.6% failure rate - the highest of any disease. Between 2003 and 2021, zero new treatments were approved while $42.5 billion was spent on clinical trials. Then lecanemab and donanemab broke through. But 27% slowing of cognitive decline, brain swelling in up to 1 in 4 patients, and $26,000/year raises the question: is this enough?
A decade of data. From Spinraza to Mounjaro, what the designations tell you.
We analyzed every novel drug the FDA approved from 2016 to 2025 - 459 drugs across 10 years - and tagged each one with its regulatory designations. Half target rare diseases. 42% are first-in-class. Breakthrough therapy doubled. From Spinraza to Mounjaro, the patterns tell you more about how the FDA works than any single approval ever could.
Every approved IBD drug fights inflammation. None of them touch fibrosis. TL1A does both.
30% of Crohn's disease patients will need surgery within ten years of diagnosis - not because their drugs failed to control inflammation, but because no approved drug stops the scar tissue that narrows their bowel. TL1A is the first target that could change that. Here is the biology behind the $18 billion bet.
How a quiet antibody program in the Netherlands became the highest-revenue drug in pharmaceutical history.
Keytruda was invented at Organon in the Netherlands, buried in two acquisitions, and became a $32B/year franchise across 20 cancer types. Nearly half of Merck's total revenue now depends on one molecule. Its US patent expires December 2028.
It took 40 years to drug KRAS. The real competition started the day it worked.
KRAS mutations drive roughly 30% of all cancers. For four decades, no one could drug it. In 2021, sotorasib cracked the target. Now three approaches - next-gen G12C, G12D inhibitors, and pan-KRAS degraders - are racing to turn a proven mechanism into a blockbuster.
A biosimilar approved in 2016. Still shelved in 2026.
Sandoz's Erelzi received FDA approval in August 2016. Nearly a decade later, it still hasn't launched in the US - while the same drug has been selling in Europe since 2017. The patent cliff is set for 2029. An antitrust challenge was dismissed in February 2026 and is now on appeal.
Amgen got FDA approval for Amjevita in September 2016. It shipped its first US vial in January 2023. Six and a half years between approval and market entry - and nine more Humira biosimilars followed the same pattern. The gap between "approved" and "on sale" isn't a quirk of Humira. It's how biologics competition works.
$6 billion in revenue. Generics launch May 2026. The decline already started.
Januvia was a $6 billion franchise for a decade. Generics launch in May 2026, but revenue is already down 64% from peak - squeezed by GLP-1 competition from above and generic anticipation from below.
How a genetic discovery in 2003 launched a $5 billion market.
In 2006, researchers found people born with broken copies of PCSK9 had very low cholesterol and almost no heart attacks. They were healthy. That was the signal. Four drugs across three different modalities now target the same gene - a combined market exceeding $5 billion in 2025.
Sickle cell disease is a single-letter typo in DNA. CRISPR can now edit DNA with precision. You'd think the fix is obvious. It's not. Casgevy uses CRISPR to reactivate fetal hemoglobin instead of correcting the mutation directly — because the indirect approach is proving safer and more effective.
The difference explains everything about how biologics compete.
When a small-molecule patent expires, generics arrive at 90% off. When a biologic patent expires, biosimilars arrive years later at a modest discount. Same industry, completely different economics. The reason is molecular.
How to read a drug name you have never seen before.
Pembrolizumab. Adalimumab. Semaglutide. These look like random syllables. They're not. Every generic drug name follows a WHO naming code that encodes the drug class, mechanism, and modality directly into its name. Once you know the suffixes, you can decode any drug on sight.
Pro gives you the data — patent cliffs, trial analytics, competitive landscapes, revenue tracking. Briefs tell the story with the data. Launch pricing: $99/month.
